# Pfizer: Observational study in Metastatic Urothelial Carcinoma, Urothelial Cancer (5122 participants)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies |
| NCT ID | NCT07897669 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | Metastatic Urothelial Carcinoma; Urothelial Cancer; Urothelial Carcinoma; Locally Advanced or Metastatic Urothelial Carcinoma; Bladder Cancer; Bladder Neoplasms |
| Target enrollment | 5122 |
| Posted | 2026-10-27 |
| Planned start | 2026-10-21 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 5122 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07897669). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.